Zurcher Kantonalbank Zurich Cantonalbank raised its stake in PAREXEL International Corporation (NASDAQ:PRXL) by 10.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,986 shares of the medical research company’s stock after purchasing an additional 180 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in PAREXEL International Corporation were worth $173,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Public Employees Retirement System of Ohio increased its stake in PAREXEL International Corporation by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 73 shares in the last quarter. Meadow Creek Investment Management LLC increased its stake in PAREXEL International Corporation by 7.1% in the first quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock valued at $125,000 after purchasing an additional 132 shares in the last quarter. Mogy Joel R Investment Counsel Inc. bought a new stake in PAREXEL International Corporation in the second quarter valued at $204,000. Invictus RG bought a new stake in PAREXEL International Corporation in the first quarter valued at $158,000. Finally, BlueCrest Capital Management Ltd bought a new stake in PAREXEL International Corporation in the first quarter valued at $202,000. 87.45% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have weighed in on PRXL shares. Zacks Investment Research downgraded shares of PAREXEL International Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. Credit Suisse Group reaffirmed a “neutral” rating and issued a $83.00 price target (up from $65.00) on shares of PAREXEL International Corporation in a research note on Tuesday, June 6th. Mizuho lifted their price target on shares of PAREXEL International Corporation from $66.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, May 30th. Goldman Sachs Group, Inc. (The) raised shares of PAREXEL International Corporation from a “sell” rating to a “neutral” rating and lifted their price target for the company from $63.00 to $77.00 in a research note on Tuesday, May 23rd. Finally, BidaskClub downgraded shares of PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company’s stock. PAREXEL International Corporation presently has a consensus rating of “Hold” and a consensus price target of $75.92.

ILLEGAL ACTIVITY NOTICE: “PAREXEL International Corporation (PRXL) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/18/parexel-international-corporation-prxl-shares-bought-by-zurcher-kantonalbank-zurich-cantonalbank.html.

Shares of PAREXEL International Corporation (PRXL) opened at 87.95 on Monday. PAREXEL International Corporation has a 52-week low of $51.16 and a 52-week high of $87.98. The stock’s 50 day moving average is $87.71 and its 200 day moving average is $77.62. The company has a market capitalization of $4.50 billion, a P/E ratio of 42.69 and a beta of 0.79.

PAREXEL International Corporation (NASDAQ:PRXL) last issued its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.08. PAREXEL International Corporation had a net margin of 4.49% and a return on equity of 28.98%. The company had revenue of $557.20 million during the quarter, compared to analysts’ expectations of $537.59 million. During the same period last year, the company posted $0.94 EPS. Equities analysts expect that PAREXEL International Corporation will post $3.95 EPS for the current year.

PAREXEL International Corporation Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.